Development and Statistical Correlation of Spectrophotometric Methods for Atazanavir Sulfate with Sulphonethalein Dyes

ANINDITA BEHERA^{1,*}, DANNANA G. SANKAR², SWAPAN K. MOITRA¹ and SUDAM C. SI¹

¹School of Pharmaceutical Sciences, Siksha 'O' Anusandhan University, Bharatpur, Ghatikia, Bhubaneswar-751 003, India

²Pharmaceutical Analysis and Quality Assurance Division, College of Pharmaceutical Sciences, Andhra University, Visakhapatnam-530 003, India

*Corresponding author: E-mail: anindita02@gmail.com

Received: 4 December 2013;

Accepted: 30 April 2014;

Published online: 6 November 2014;

AJC-16182

Two simple, extraction free spectrophotometric methods are proposed for analysis of protease inhibitor, *i.e.*, atazanavir sulfate. The methods are based on interaction of the drug with 0.1 % chloroformic solutions of acidic sulphonethalein dyes to form stable yellow coloured ion pair complexes. Two dyes used are bromophenol blue and bromothymol blue. The yellow chromogens are stable and show absorption maxima at 421.9 and 419.4 nm with bromophenol blue and bromothymol blue, respectively. The two chromogens follow the linearity in the range of 5-30 and 10-30 µg/mL for bromophenol blue and bromothymol blue respectively. Both methods are validated according to ICH guidelines and statistically compared.

Keywords: Atazanavir sulfate, Bromophenol blue, Bromothymol blue, Two way ANOVA, Student's *t*-test.

INTRODUCTION

Atazanavir sulfate (ATV) (3S,8S,9S,12S)-3,12-*bis*(1,1-dimethylethyl)-8-hydroxy-4,11-dioxo-9-(phenylmethyl)-6-[[4-(2-pyridinyl)phenyl]methyl]-2,5,6,10,13-pent-aazatetradecane dioic acid dimethyl ester (Fig. 1), an aza-peptide is the 7th protease inhibitor used in the treatment of human immunodeficiency virus (HIV) Type II infection¹. Atazanavir sulfate is official in IP 2010². Atazanavir sulfate is reported as poorly water soluble and a known substrate for both hepatic metabolizing enzyme cytochrome 450 (CYP3A) and intestinal drug efflux pump, P-glycoprotein (Pgp) so have low oral bio-availability³. In literature several methods of analysis are reported for determination of atazanavir sulfate in blood plasma, biological cells and cerebrospinal fluid by HPLC⁴⁻²⁵. Stress degradation studies which were reported, analyzed by HPLC and ultraviolet-spectrophotometry^{26,27}. The authors have reported spectrophotometric methods²⁸ and HPLC method²⁹ in pharmaceutical dosage form. The present work is developed to simplify the extractive spectrophotometric methods using two sulphonethalein dyes, *i.e.* bromophenol blue and bromothymol blue.

EXPERIMENTAL

Reference standard and raw material of atazanavir sulfate were procured from Matrix Laboratories (Hyderabad, India) as gift sample. Solvents used like chloroform, bromophenol

blue (BPB) bromothymol blue (BTB) were of analytical grade. Two brands of capsules Atavir 300 (Cipla) and Atazor 200 (Emcure) were purchased from local market.

Preparation of standard solution of atazanavir sulfate:

A stock solution of atazanavir sulfate of concentration 100 µg/mL was prepared by dissolving 10 mg of atazanavir sulfate in 100 mL of chloroform. Serial dilutions were prepared by taking the aliquots of stock solution each in 10 mL volumetric flasks and diluting with chloroform.

Preparation of reagent solutions: 0.1 % w/v chloroformic solution of bromophenol blue was prepared by dissolving 10 mg of bromophenol blue in 10 mL of chloroform. 0.1 % chloroformic solution of bromothymol blue was prepared by dissolving 10mg of bromothymol blue in 10 mL of chloroform.

Procedure for bromophenol blue: Aliquots 0.5-3.0 mL of standard atazanavir sulfate was transferred to a series of 10 mL volumetric flask. To that 2 mL of 0.1 % chloroformic bromophenol blue was added and kept aside for development of a yellowish chromogen. After 5 min the volume was made up to the mark with chloroform. The resulting solution was scanned against the blank from 380-780 nm for determination of λ_{max} .

Procedure for bromothymol blue: Aliquots 1-3 mL of standard atazanavir sulfate was transferred to a series of 10 mL volumetric flask. To that 1 mL of 0.1 % chloroformic bromothymol blue was added and kept aside for development of a yellowish orange chromogen. After 5 min the volume

Fig. 1. Chemical structure of atazanavir sulfate (ATV)

was made up to the mark with chloroform. The resulting solution was scanned against the blank from 380-780 nm for determination of $\lambda_{\max}$.

Procedure for sample: Capsules of atazanavir sulfate were purchased from the local market. Contents of capsules were taken out and weighed. Equivalent amount of atazanavir sulfate was calculated and dissolved in chloroform to prepare the solution of 100 $\mu\text{g/mL}$. The sample was treated in the same way with bromophenol blue and bromothymol blue respectively and analyzed at $\lambda_{\max}$.

Validation: Both the methods were validated as per ICH guidelines³⁰. The methods are validated in terms of accuracy and precision, limit of detection (LOD) and limit of quantitation (LOQ), specificity and selectivity.

Statistical analysis: To correlate the difference between the two developed methods of spectrophotometry, six different samples were taken from two different brands and quantification was done simultaneously. To test difference between the proposed spectrophotometric methods statistical tests were performed for the level of confidence 95 % ($P = 0.05$). Two way ANOVA and student's t-test were applied to test the significant difference between both the methods.

RESULTS AND DISCUSSION

In **method A**, the drug was allowed to react with bromophenol blue and in **method B**, the drug was reacted with bromothymol blue in neutral medium. As compared to the reported spectrophotometric method by Behera *et al.*²⁸, the present methods are equally significant from the point of validation parameters and the present work demonstrates the simplified extraction free, ion complexation estimation by

spectrophotometric method. The methods are easier than the conventional methods of ion complex estimation by extraction in suitable buffer system. The difficulties in choice of suitable buffer system, preparation and maintenance of buffer system and extraction in suitable organic solvent are overcome by the proposed methods. Statistical correlation of the two methods signifies that there is no significant difference between two developed methods.

Optical characteristics: The absorption spectra of yellowish coloured chromogen of atazanavir sulfate and bromophenol blue had $\lambda_{\max}$ at 421.9 nm and the yellowish orange product of atazanavir sulfate and bromothymol blue had $\lambda_{\max}$ at 419.4 nm, respectively. The absorption spectra are shown in Figs. 2 and 3. The wavelengths were used for the validation of the methods. The linearity for **method A** was found at 5-30 $\mu\text{g/mL}$ and for **method B** at 10-30 $\mu\text{g/mL}$ respectively. The different optical parameters are listed in Table-1.

Fig. 2. Absorption spectra of atazanavir sulfate-bromophenol blue (ATV-BPB) chromogen having $\lambda_{\max}$ at 421.9 nm

Fig. 3. Absorption spectra of atazanavir sulfate-bromothymol blue (ATV-BTB) chromogen having $\lambda_{\max}$ at 419.4 nm

TABLE-1
OPTICAL CHARACTERISTICS OF METHOD A AND B

Parameters	Method A Atazanavir sulfate (ATV) + Bromophenol blue (BPB)	Method B Atazanavir sulfate (ATV) + Bromothymol blue (BTB)
$\lambda_{\max}$ (nm)	421.9	419.4
Colour	Yellowish	Yellowish Orange
Stability (h)	2	3
Beer's law range ($\mu\text{g/mL}$)	5 - 30	10 - 30
Limit of detection ($\mu\text{g/mL}$)	0.167	0.325
Limit of quantification ($\mu\text{g/mL}$)	0.506	0.984
Molar absorptivity ($\text{l mol}^{-1} \text{cm}^{-1}$)	4.67×10^3	2.24×10^3
Sandell's sensitivity ($\mu\text{g cm}^{-2}$)	0.058	0.096
Regression equation [$Y = mX + c$]		
Slope (m)	0.001	0.021
Intercept (c)	0.0846	0.089
Correlation coefficient (r)	0.999	0.998

Optimization of reagent concentration: Optimization of reagents in terms of volume and concentration are very essential to develop a spectrophotometric method. For **method A**, concentration and volume of bromophenol blue were optimized by taking concentration of 0.05-0.2 % of bromophenol blue and volume of 0.5-2.5 mL. For bromophenol blue 0.1 % concentration of 2 mL volume of bromophenol blue gave the satisfactory colour. For **method B**, concentration and volume of bromothymol blue were optimized by taking concentration of 0.05-0.2 % of bromothymol blue and volume of 0.5-2.5 mL. For bromothymol blue 0.1 % concentration of 1 mL volume of bromothymol blue gave the satisfactory colour.

Assay of formulation: Two different formulations were assayed by the developed methods. The two formulation content were determined and expressed in terms of mean $\pm$ standard deviation and represented in Table-2.

Accuracy and precision: Accuracy of both the methods was done by recovery study by standard addition method. Standard drug was added to pre-analyzed solution of formulations at the level of 25, 50 and 100 %. Lower value of standard deviation signifies the accuracy of the methods (Table-3). Precision was evaluated by mean $\pm$ standard deviation of inter-day and intra-day assay (Table-4).

Limit of detection and limit of quantification: The limit of detection (LOD) and limit of quantification (LOQ) for both

the methods with bromophenol blue and bromothymol blue were found to be 0.167 and 0.325 $\mu\text{g/mL}$ and 0.506 and 0.984 $\mu\text{g/mL}$, respectively.

Specificity and selectivity: Both the methods were done in presence of excipients and changing the reaction conditions slightly. In presence of excipients, no interference was found. The reaction conditions were varied like change of reaction medium, variation in strength and volume of reagents altered the results, which signifies the selectivity of the methods.

Reaction sequence: The sulphonephthalein dyes like bromophenol blue and bromothymol blue exist in lactoid and quinoid tautomeric form. The quinoid form liberates a proton and the anion forms the ion pairing with protonated atazanavir sulfate represented in **Scheme-I**. Rahman and Azmi³¹, suggested that the quinoid form predominates the lactoid form in strong acidic medium and the opening of lactoid ring is responsible for formation of coloured chromogen with protonated drug. The reaction of atazanavir sulfate with bromophenol blue and bromothymol blue is represented in **Schemes I and II** respectively. The present method is developed to avoid the complexity of extraction of ion pair complex at a suitable pH. As the method is extraction free and no buffer is used for extraction of ion pair complex, the method is rapid. The ion pair complexes are easily extractable in chloroform, the method is simple. The methods are compared with the previously reported methods^{28,29} and found to be equally significant.

TABLE-2
ASSAY OF ATAZANAVIR SULFATE IN PHARMACEUTICAL FORMULATIONS

Name of the formulation	Label claim (mg)	Amount of drug found (mg) Mean* $\pm$ S.D	
		Method A (Atazanavir sulfate (ATV) + Bromophenol blue (BPB))	Method B (Atazanavir sulfate (ATV) + Bromothymol blue (BTB))
Atavir 300	300	299.78 $\pm$ 0.5	298.08 $\pm$ 0.02
Atazor 200	200	199.63 $\pm$ 0.6	200.99 $\pm$ 0.6

*Mean of five determinations

TABLE-3
ACCURACY OF THE METHOD (RECOVERY STUDY)

Name of the formulation	Method A [Atazanavir sulfate (ATV) + Bromophenol blue (BPB)]			Method B [Atazanavir sulfate (ATV) + Bromothymol blue (BTB)]		
	Amount of sample taken ($\mu\text{g/mL}$)	Amount of standard taken ($\mu\text{g/mL}$)	Amount found ($\mu\text{g/mL}$) Mean* $\pm$ S.D	Amount of sample taken ($\mu\text{g/mL}$)	Amount of standard taken ($\mu\text{g/mL}$)	Amount found ($\mu\text{g/mL}$) Mean* $\pm$ S.D
Atavir 300	20	5	24.94 $\pm$ 0.03	4	1	5.00 $\pm$ 0.07
	20	10	29.79 $\pm$ 0.03	4	2	6.04 $\pm$ 0.03
	20	20	39.82 $\pm$ 0.04	4	4	7.91 $\pm$ 0.04
Atazor 200	20	5	25.01 $\pm$ 0.03	4	1	4.96 $\pm$ 0.03
	20	10	30.01 $\pm$ 0.06	4	2	5.92 $\pm$ 0.03
	20	20	40.00 $\pm$ 0.06	4	4	7.99 $\pm$ 0.04

*Mean of five determinations

TABLE-4
PRECISION OF THE METHODS

Name of the formulation	Intra-day precision (n = 5) Mean* (mg) $\pm$ S.D		Inter-day precision (n = 3) Mean* (mg) $\pm$ S.D	
	Method A	Method B	Method A	Method B
	Atazanavir sulfate (ATV) + Bromophenol blue (BPB)	Atazanavir sulfate (ATV) + Bromothymol blue (BTB)	Atazanavir sulfate (ATV) + Bromophenol blue (BPB)	Atazanavir sulfate (ATV) + Bromothymol blue (BTB)
Atavir 300	299.95 $\pm$ 0.6	300.16 $\pm$ 0.26	299.83 $\pm$ 0.15	299.17 $\pm$ 0.03
Atazor 200	200.9 $\pm$ 0.15	200.04 $\pm$ 0.26	200.06 $\pm$ 0.06	200.12 $\pm$ 0.04

*Mean of five determinations

Scheme-I

Statistical analysis: Two way ANOVA was applied to test both method-sample interaction and differences in method precision. In both the cases $F_{stat} < F_{crit}$, signifying the method

-sample interaction and the differences between the methods are not significant (Table-5).

TABLE-5
TWO WAY ANOVA TEST OF ATAZANAVIR SULFATE (ATV) BY DETERMINATION
IN SIX INDEPENDENT SAMPLES IN DUPLICATE BY METHOD A AND B

153A INDEPENDENT SAMPLES IN DUPLICATE BY METHOD A AND B						
Sample	Method A			Method B		
	Atazanavir sulfate (ATV) + Bromophenol blue (BPB)		Atazanavir sulfate (ATV) + Bromothymol blue (BTB)			
	Atavir*	Atazor*	Atavir*	Atazor*		
1	99.53	99.92	99.86	99.78		
2	98.79	99.83	98.64	99.84		
3	100.03	98.75	98.88	99.55		
4	99.82	99.65	99.69	100.05		
5	99.64	98.87	100.04	99.56		
6	99.88	99.59	99.75	98.87		
ANOVA: Two-factor with replication						
Source of variation	SS	df	MS	F	P-value	F crit
Sample	0.0035	1	0.0035	0.015	0.904	4.3512
Columns	0.0018	1	0.0018	0.008	0.9303	4.3512
Interaction	0.1457	1	0.1457	0.621	0.4399	4.3512
Within	4.6925	20	0.2346	-	-	-
Total	4.8435	23	-	-	-	-

$F_{stat} < F_{crit}$

*Results are presented as % of mg of label claim of ATV in capsules

Scheme-II

TABLE-6
AVERAGE RESULTS OF ATAVIR (a) AND ATAZOR (b)
DETERMINATION BY METHOD A AND B AND THEIR
CORRELATION BY PAIRED *t*-test

Sample	Method A [#]	Method B [#]
(a) Atavir		
1	99.53	99.86
2	98.79	98.64
3	100.03	98.88
4	99.82	99.69
5	99.64	100.04
6	99.88	99.75
Average	99.615	99.476
<i>t</i> -test: Paired two sample for means		
	Variable 1	Variable 2
Mean	99.615	99.4766
Variance	0.1945	0.3281
Observations	6	6
Pearson Correlation	0.4276	
Hypothesized Mean Difference	0	
df	5	
<i>t</i> Stat	0.612	
P(T < = <i>t</i>) one-tail	0.2836	
<i>t</i> Critical one-tail	2.015	
P(T < = <i>t</i>) two-tail	0.5673	
<i>t</i> Critical two-tail	2.5705	
<i>t</i> Stat < <i>t</i> critical		

Sample	Method A*	Method B*
(b) Atazor		
1	99.92	99.78
2	99.83	99.84
3	98.75	99.55
4	99.65	100.05
5	98.87	99.56
6	99.59	98.87
Average	99.435	99.60
<i>t</i> -test: Paired two sample for means		
	Variable 1	Variable 2
Mean	99.435	99.608
Variance	0.25	0.166
Observations	6	6
Pearson Correlation	0.219	-
Hypothesized Mean Difference	0	-
df	5	-
<i>t</i> Stat	-0.742	-
P(T < = <i>t</i>) one-tail	0.245	-
<i>t</i> Critical one-tail	2.015	-
P(T < = <i>t</i>) two-tail	0.491	-
<i>t</i> Critical two-tail	2.57	-
<i>t</i> Stat < <i>t</i> critical	-	-

[#]Results are presented as % of mg of label claim of ATV in Atavir capsules, *Results are presented as % of mg of label claim of ATV in Atazor capsules

To test means a paired student's *t*-test was applied. The test removes any variation between samples. From the student's *t*-test, *t* stat < *t* crit was found in both the cases signifying there is no significant difference between the means (Table-6).

Conclusion

The developed methods were validated and found to be simple, accurate and precise. The developed methods are equally significant with the reported methods. The instrument and the chemicals used in the developed methods are easily available in any small laboratories, so these methods can be used for both qualitative and quantitative estimation of atazanavir sulfate in bulk and dosage form.

ACKNOWLEDGEMENTS

The authors are thankful to Siksha 'O' Anusandhan University for providing the research facilities to carry out the research work.

REFERENCES

1. K. Fukushima, S. Terasaka, K. Haraya, S. Kodera, Y. Seki, A. Wada, Y. Ito, N. Shibata, N. Sugioka and K. Takada, *Biol. Pharm. Bull.*, **30**, 733 (2007).
2. The Indian Pharmacopoeia, Indian Pharmacopoeia Commission: Ghaziabad, India, Vol. 2, p. 844 (2010).
3. E.S. Perloff, S.X. Duan, P.R. Skolnik, D.J. Greenblatt and L.L. von Moltke, *Drug Metab. Dispos.*, **33**, 764 (2005).
4. R. ter Heine, M. Davids, H. Rosing, E.C.M. van Gorp, J.W. Mulder, Y.T. van der Heide, J.H. Beijnen and A.D.R. Huitema, *J. Chromatogr. B*, **877**, 575 (2009).
5. R. ter Heine, H. Rosing, E.C.M. van Gorp, J.W. Mulder, W.A. van der Steeg, J.H. Beijnen and A.D.R. Huitema, *J. Chromatogr. B*, **867**, 205 (2008).
6. A. D'Avolio, M. Siccardi, M. Sciandra, B. Lorena, S. Bonora, L. Trentini and G. Di Perri, *J. Chromatogr. B*, **859**, 234 (2007).
7. R. ter Heine, C.G. Alderden Los, H. Rosing, M.J.X. Hillebrand, E.C.M. van Gorp, A.D.R. Huitema and J.H. Beijnen, *Rapid Commun. Mass Spectrom.*, **21**, 2505 (2007).
8. L. Dickinson, L. Robinson, J. Tjia, S. Khoo and D. Back, *J. Chromatogr. B*, **829**, 82 (2005).
9. T. Koal, H. Burhenne, R. Römmling, M. Svoboda, K. Resch and V. Kaever, *Rapid Commun. Mass Spectrom.*, **19**, 2995 (2005).
10. S. Colombo, A. Beguin, A. Telenti, J. Biollaz, T. Buclin, B. Rochat and L.A. Decosterd, *J. Chromatogr. B*, **819**, 259 (2005).
11. K.M.L. Crommentuyn, H. Rosing, M.J.X. Hillebrand, A.D.R. Huitema and J.H. Beijnen, *J. Chromatogr. B*, **804**, 359 (2004).
12. M. Jemal, S. Rao, M. Gatz and D. Whigan, *J. Chromatogr. B*, **795**, 273 (2003).
13. A. Schuster, S. Burzawa, M. Jemal, E. Loizillon, P. Couerbe and D. Whigan, *J. Chromatogr. B*, **788**, 377 (2003).
14. D. Cattaneo, F. Maggiolo, D. Ripamonti and N. Perico, *J. Chromatogr. Sci.*, **46**, 485 (2008).
15. U. Seshachalam, D.V.L.N. Rao, B. Haribabu and K.B. Chandrasekhar, *Chromatographia*, **65**, 355 (2007).
16. K. Keil, J. Hochreiter, R. DiFrancesco, B.S. Zingman, R.C. Reichman, M.A. Fischl, B. Gripshover and G.D. Morse, *Ther. Drug Monit.*, **29**, 103 (2007).
17. R. Verbesselt, E. van Wijngaerden and J. de Hoon, *J. Chromatogr. B*, **845**, 51 (2007).
18. A. Loregian, S. Pagni, E. Ballarin, E. Sinigaglia, S.G. Parisi and G. Palu, *J. Pharm. Biomed. Anal.*, **42**, 500 (2006).
19. N.L. Rezk, R.D. Crutchley, R.F. Yeh and A.D.M. Kashuba, *Ther. Drug Monit.*, **28**, 517 (2006).
20. R.W. Sparidans, F. Dost, K.M.L. Crommentuyn, A.D.R. Huitema, J.H.M. Schellens and J.H. Beijnen, *Biomed. Chromatogr.*, **20**, 72 (2006).
21. E. Cateau, N. Tournier, A. Dupuis, G.L. Moal and N. Venisse, *J. Pharm. Biomed. Anal.*, **39**, 791 (2005).
22. O. Tribut, M.C. Verdier, C. Arvieux, H. Allain, C. Michelet and D. Bentue-Ferrer, *Ther. Drug Monit.*, **27**, 265 (2005).
23. J.M. Poirier, P. Robidou and P. Jaillon, *Ther. Drug Monit.*, **27**, 186 (2005).
24. E. Dailly, F. Raffi and P. Joliet, *J. Chromatogr. B*, **813**, 353 (2004).
25. S. Colombo, N. Guignard, C. Marzolini, A. Telenti, J. Biollaz and L.A. Decosterd, *J. Chromatogr. B*, **810**, 25 (2004).
26. S.R. Chitturi, Y.S. Somannavar, B.G. Peruri, S. Nallapati, H.K. Sharma, S.R. Budidet, V.K. Handa and H.B. Vurimindi, *J. Pharm. Biomed. Anal.*, **55**, 31 (2011).
27. S. Dey, Y.V. Reddy, T. Reddy, S.K. Sahoo, P.N. Murthy, S. Mohapatra and S.S. Patro, *Int. J. Pharm. Bio. Sci.*, **1**, 1 (2010).
28. A. Behera, S.K. Moitra, S.C. Si and D.G. Sankar, *Quim. Nova*, **34**, 1349 (2011).
29. A. Behera, D.G. Sankar, S.K. Moitra and S.C. Si, *E.-J. Chem.*, **9**, 1778 (2012).
30. ICH Guideline, Q2(R1): Validation of Analytical Procedures: Text and Methodology, International Conference on Harmonization, Geneva (2005).
31. N. Rahman and S.N. Hejaz-Azmi, *J. Pharm. Biomed. Anal.*, **24**, 33 (2000).